Evidence map›Paper›PMID 33062197›Full record

ArticleOncotarget2020

Correction: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.

Adrienne L Watson, Bryant J Keller, Kyle A Williams, Namrata N Damle, Samuel J Finnerty, Leah K Anderson, Andrew D Greeley, Vincent W Keng, Eric P Rahrmann, Amanda L Halfond and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Adrienne L Watson *Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Bryant J Keller *Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Kyle A WilliamsMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Namrata N DamleMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Samuel J FinnertyMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Leah K AndersonMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Andrew D GreeleyMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Vincent W KengMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Eric P RahrmannMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Amanda L HalfondHealth and Natural Sciences Department, University of Minnesota, Minneapolis, MN, USA.
Natasha M PowellBrain Tumor Program, University of Minnesota, Minneapolis, MN, USA.
Margaret H CollinsDivision of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Tilat RizviDivision of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Christopher L MoertelDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Nancy RatnerDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
David A LargaespadaMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.1609.].

Identifiers

PMID33062197
PMCPMC7533073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.